Advertisement
CAH vs COR
Which Stock Would AI Choose? Cardinal Health (CAH) vs. Cencora (COR) Stock Comparison
Key Takeaways
- Both CAH and COR operate as major pharmaceutical distributors in the healthcare sector, benefiting from steady demand for specialty drugs and distribution services.
- CAH has delivered stronger recent momentum, with approximately 12% year-to-date gains and notable outperformance relative to broader market benchmarks in recent market activity.
- COR has shown signs of recovery, including double-digit percentage gains over select 30-day periods amid consolidation ahead of earnings.
- Upcoming quarterly results for both companies in early August provide near-term catalysts that could influence sentiment and volatility.
- Key contrasts include CAH’s focus on home-care expansion versus COR’s established international footprint and dividend growth history.
- Relative positioning highlights trade-offs between CAH’s turnaround execution and COR’s longer-term stability metrics.
Introduction
Cardinal Health (CAH) and Cencora (COR) represent two leading players in pharmaceutical distribution, making them natural subjects for comparison among investors seeking exposure to healthcare logistics and specialty pharmaceuticals. Traders and portfolio managers evaluating sector rotation, relative value, or momentum strategies in the current market environment may find this analysis useful for assessing positioning, risk factors, and performance differentials between the two stocks.
CAH Overview and Recent Performance
Cardinal Health (CAH) provides medical products, pharmaceutical distribution, and specialty services across the United States and select international markets. In recent market activity, the stock has exhibited positive momentum, posting approximately 12% year-to-date returns and outpacing the S&P 500 over broader trailing periods, supported by strong demand for specialty pharmaceuticals. Recent developments include tuck-in acquisitions to expand the home-care business and multiple upward revisions to annual profit guidance, which have contributed to favorable sentiment despite a premium valuation reflected in an elevated price-to-earnings ratio. Short-term price behavior has included periods of consolidation and modest pullbacks amid broader market fluctuations.
COR Overview and Recent Performance
Cencora (COR), formerly AmerisourceBergen, specializes in pharmaceutical distribution, specialty solutions, and global supply-chain services. The stock has experienced mixed performance in recent weeks, with notable recovery gains of around 13% over certain 30-day windows following earlier consolidation, even as year-to-date results remain negative. Key influences include upcoming third-quarter earnings and analyst target adjustments, alongside a focus on maintaining adjusted earnings-per-share guidance. Market activity has featured volatility around earnings anticipation and sector-specific news flow, with the shares trading in the middle of their 52-week range in recent sessions.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a broader universe of hundreds available on the platform. These bots trade thousands of different tickers across equities, with only the most suitable for prevailing market conditions earning placement in the trending section. Available bots feature diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with many demonstrating historical win rates in ranges such as 60-80% alongside varying risk-reward profiles. This dynamic environment allows users to explore automated approaches tailored to individual objectives. For more details, visit Trending AI Robots.
Head-to-Head Comparison
Both companies share a core business model centered on pharmaceutical distribution and specialty services, exposing them to similar secular tailwinds in drug utilization and healthcare spending. Growth drivers differ in emphasis, with CAH pursuing aggressive expansion in home care and specialty verticals, while COR leverages a broader international presence and a longer dividend growth streak. Recent momentum has favored CAH on a relative basis, though COR has demonstrated resilience through recovery phases. Risk factors for CAH include elevated valuations and execution on acquisitions, whereas COR contends with periodic revenue forecast adjustments and post-earnings volatility. Sector exposure remains comparable within healthcare distribution, yet market sentiment reflects divergent short-term narratives around guidance revisions and operational focus.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning, Tickeron’s AI would likely express a marginal preference for COR in the current environment. The assessment draws from the company’s established track record of double-digit adjusted earnings growth, international diversification, and mature specialty platform, which together suggest a potentially more durable trajectory. However, CAH presents a compelling alternative for those prioritizing recent momentum and operational acceleration, with outcomes dependent on execution over subsequent quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAH is a Buy and COR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CAH’s FA Score shows that 2 FA rating(s) are green whileCOR’s FA Score has 2 green FA rating(s).
- CAH’s FA Score: 2 green, 3 red.
- COR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CAH’s TA Score shows that 4 TA indicator(s) are bullish while COR’s TA Score has 6 bullish TA indicator(s).
- CAH’s TA Score: 4 bullish, 4 bearish.
- COR’s TA Score: 6 bullish, 4 bearish.
Price Growth
CAH (@Medical Distributors) experienced а +0.88% price change this week, while COR (@Medical Distributors) price change was +0.47% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +3.12%. For the same industry, the average monthly price growth was +0.99%, and the average quarterly price growth was -11.33%.
Reported Earning Dates
CAH is expected to report earnings on Aug 11, 2026.
COR is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Medical Distributors (+3.12% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| CAH | COR | CAH / COR | |
| Capitalization | 53.9B | 60.6B | 89% |
| EBITDA | 3.27B | 5.03B | 65% |
| Gain YTD | 12.732 | -7.449 | -171% |
| P/E Ratio | 35.12 | 23.86 | 147% |
| Revenue | 251B | 329B | 76% |
| Total Cash | N/A | 2.18B | - |
| Total Debt | 8.92B | 12.4B | 72% |
CAH | COR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 29 | |
SMR RATING 1..100 | 100 | 12 | |
PRICE GROWTH RATING 1..100 | 43 | 49 | |
P/E GROWTH RATING 1..100 | 20 | 81 | |
SEASONALITY SCORE 1..100 | 28 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COR's Valuation (68) in the Real Estate Investment Trusts industry is in the same range as CAH (71) in the Medical Distributors industry. This means that COR’s stock grew similarly to CAH’s over the last 12 months.
CAH's Profit vs Risk Rating (5) in the Medical Distributors industry is in the same range as COR (29) in the Real Estate Investment Trusts industry. This means that CAH’s stock grew similarly to COR’s over the last 12 months.
COR's SMR Rating (12) in the Real Estate Investment Trusts industry is significantly better than the same rating for CAH (100) in the Medical Distributors industry. This means that COR’s stock grew significantly faster than CAH’s over the last 12 months.
CAH's Price Growth Rating (43) in the Medical Distributors industry is in the same range as COR (49) in the Real Estate Investment Trusts industry. This means that CAH’s stock grew similarly to COR’s over the last 12 months.
CAH's P/E Growth Rating (20) in the Medical Distributors industry is somewhat better than the same rating for COR (81) in the Real Estate Investment Trusts industry. This means that CAH’s stock grew somewhat faster than COR’s over the last 12 months.
| CAH | COR | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 45% | 4 days ago 46% |
| Stochastic ODDS (%) | 4 days ago 53% | 4 days ago 48% |
| Momentum ODDS (%) | 4 days ago 72% | 4 days ago 64% |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 65% |
| TrendWeek ODDS (%) | 4 days ago 66% | 4 days ago 62% |
| TrendMonth ODDS (%) | 4 days ago 42% | 4 days ago 63% |
| Advances ODDS (%) | 7 days ago 66% | 7 days ago 61% |
| Declines ODDS (%) | 5 days ago 43% | 4 days ago 43% |
| BollingerBands ODDS (%) | 4 days ago 82% | 4 days ago 50% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 61% |
Advertisement
CAH and
Correlation & Price change
A.I.dvisor indicates that over the last year, CAH has been closely correlated with MCK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAH jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To CAH | 1D Price Change % | ||
|---|---|---|---|---|
| CAH | 100% | +1.30% | ||
| MCK - CAH | 67% Closely correlated | -1.08% | ||
| COR - CAH | 58% Loosely correlated | -0.29% | ||
| FOCL - CAH | 9% Poorly correlated | -0.33% | ||
| YI - CAH | 5% Poorly correlated | +3.89% | ||
| HSIC - CAH | 1% Poorly correlated | +0.68% | ||
More | ||||
COR and
Correlation & Price change
A.I.dvisor indicates that over the last year, COR has been closely correlated with MCK. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if COR jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To COR | 1D Price Change % | ||
|---|---|---|---|---|
| COR | 100% | -0.29% | ||
| MCK - COR | 70% Closely correlated | -1.08% | ||
| CAH - COR | 57% Loosely correlated | +1.30% | ||
| FOCL - COR | 7% Poorly correlated | -0.33% | ||
| HSIC - COR | 5% Poorly correlated | +0.68% | ||
| YI - COR | 3% Poorly correlated | +3.89% | ||
More | ||||